Solid Biosciences Announces Stockholder Approval of Acquisition of AavantiBio
December 01, 2022 16:15 ET
|
Solid Biosciences Inc.
- Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases - CHARLESTOWN, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc....
Solid Biosciences to Participate at the Piper Sandler 34th Annual Healthcare Conference
November 22, 2022 08:00 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Provides Third Quarter 2022 Business Update and Financial Results
November 10, 2022 07:34 ET
|
Solid Biosciences Inc.
- Recently presented preclinical data support potential benefits of next-generation Duchenne gene therapy candidate SGT-003; program on track for mid-2023 Investigational New Drug (IND) submission - ...
Solid Biosciences Announces a 1-for-15 Reverse Stock Split
October 27, 2022 08:00 ET
|
Solid Biosciences Inc.
- Effective at 5 pm ET October 27, 2022 - CHARLESTOWN, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful...
Solid Biosciences Reports Additional Preclinical Data Demonstrating that its Novel Capsid, AAV-SLB101, Provides Superior Transduction Efficiency and Enhanced Distribution to Skeletal Muscle
October 17, 2022 08:00 ET
|
Solid Biosciences Inc.
- AAV-SLB101 is the capsid used in SGT-003, Solid’s next-generation Duchenne gene therapy, expected to enter the clinic in late-2023 - - Additional novel capsids based on AAV-SLB101 binding...
Solid Biosciences Presents New SGT-001 IGNITE DMD Study Results at World Muscle Society 2022 Congress Demonstrating Improvements in Ambulatory Function
October 13, 2022 08:00 ET
|
Solid Biosciences Inc.
- Stride velocity 95th centile (SV95C) data demonstrate improvements at one-year post-dosing compared with declines observed in control and natural history patients - - SV95C is an objective,...
Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement
September 30, 2022 07:00 ET
|
Solid Biosciences Inc.
- Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases, led by industry veteran and current AavantiBio CEO, Bo Cumbo - - Strong...
Solid Biosciences to Participate at Upcoming Investor Conferences
September 29, 2022 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Provides Second Quarter 2022 Business Update and Financial Results
August 11, 2022 07:53 ET
|
Solid Biosciences Inc.
- Transition to transient transfection-based manufacturing process continues for SGT-001; Company expects to continue dosing patients in 2023 - - Development of next-generation Duchenne gene therapy...
Solid Biosciences to Present at Upcoming Scientific and Patient Advocacy Conferences
June 23, 2022 08:00 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...